Naftopidil (INN, marketed under the brand name Flivas) is a drug used in benign prostatic hyperplasia which acts as a selective α1-adrenergic receptor antagonist or alpha-1 blocker.[1]
Clinical data | |
---|---|
Trade names | Flivas |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.220.557 |
Chemical and physical data | |
Formula | C24H28N2O3 |
Molar mass | 392.499 g·mol−1 |
3D model (JSmol) | |
| |
|
Synthesis
editThe reaction of 1-naphthol (1) with epichlorohydrin (2) in the presence of alkali gives the epoxide (3). Alkylation of the piperazine derivative (4) yields naftopidil.[2][3][4]
See also
editReferences
edit- ^ Sakai H, Igawa T, Onita T, Furukawa M, Hakariya T, Hayashi M, et al. (January 2011). "[Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication]". Hinyokika Kiyo. Acta Urologica Japonica. 57 (1): 7–13. PMID 21304253.
- ^ US patent 3997666, Witte EC, Stach K, Thiel M, Sponer G, Roesch E, "1-[3-(Naphth-1-yloxy)-2-hydroxypropvl]-piperazine compounds and therapeutic compositions", issued 1976-12-14, assigned to Boehringer Mannheim GmbH
- ^ Pujala B, Chakraborti AK (May 2007). "Zinc(II) perchlorate hexahydrate catalyzed opening of epoxide ring by amines: applications to synthesis of (RS)/(R)-propranolols and (RS)/(R)/(S)-naftopidils". The Journal of Organic Chemistry. 72 (10): 3713–3722. doi:10.1021/jo062674j. PMID 17411096.
- ^ "Naftopidil". Pharmaceutical Substances. Thieme. Retrieved 2024-07-12.